Taher Nassar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5501287/publications.pdf

Version: 2024-02-01

41 papers	1,726 citations	279798 23 h-index	289244 40 g-index
41 all docs	41 docs citations	41 times ranked	2491 citing authors

#	Article	IF	Citations
1	Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17498-17503.	7.1	119
2	Platelet Factor 4 Enhances the Binding of Oxidized Low-density Lipoprotein to Vascular Wall Cells. Journal of Biological Chemistry, 2003, 278, 6187-6193.	3.4	116
3	In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood, 2004, 103, 897-902.	1.4	106
4	Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model. Small, 2013, 9, 4221-4236.	10.0	98
5	Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. Journal of Controlled Release, 2009, 133, 77-84.	9.9	95
6	Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface. Blood, 2002, 99, 3613-3622.	1.4	93
7	Human Î±-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptorâ€“related protein/Î±2-macroglobulin receptor. Blood, 2002, 100, 4026-4032.	1.4	87
8	The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. Journal of Controlled Release, 1997, 46, 59-73.	9.9	82
9	A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicology and Applied Pharmacology, 2010, 246, 83-90.	2.8	82
10	Bloodâ€“brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology, 2010, 58, 972-980.	4.1	77
11	Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nature Neuroscience, 2006, 9, 1150-1155.	14.8	69
12	A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity. Journal of Medicinal Chemistry, 2016, 59, 9035-9046.	6.4	59
13	Determination of lipoic acid and dihydrolipoic acid in human plasma and urine by high-performance liquid chromatography with fluorimetric detection. Journal of Chromatography A, 2000, 870, 381-388.	3.7	52
14	Binding of Urokinase to Low Density Lipoprotein-related Receptor (LRP) Regulates Vascular Smooth Muscle Cell Contraction. Journal of Biological Chemistry, 2002, 277, 40499-40504.	3.4	50
15	Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. Journal of Controlled Release, 2015, 217, 202-210.	9.9	46
16	The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 248-259.	4.3	43
17	Urokinaseâ€derived peptides regulate vascular smooth muscle contractionin vitroandin vivo. FASEB Journal, 2000, 14, 1411-1422.	0.5	35
18	A Novel Nanocapsule Delivery System to Overcome Intestinal Degradation and Drug Transport Limited Absorption of P-glycoprotein Substrate Drugs. Pharmaceutical Research, 2008, 25, 2019-2029.	3.5	34

#	Article	IF	Citations
19	High Plasma Levels and Effective Lymphatic Uptake of Docetaxel in an Orally Available Nanotransporter Formulation. Cancer Research, 2011, 71, 3018-3028.	0.9	34
20	The design and evaluation of a novel targeted drug delivery system using cationic emulsionâ€“antibody conjugates. Journal of Controlled Release, 2005, 108, 418-432.	9.9	33
21	Novel Interactions between Urokinase and Its Receptor. Journal of Biological Chemistry, 2000, 275, 24304-24312.	3.4	32
22	Neuroprotection by glucagon: role of gluconeogenesis. Journal of Neurosurgery, 2011, 114, 85-91.	1.6	26
23	Regulation of Airway Contractility by Plasminogen Activators through N-Methyl-D-Aspartate Receptorâ€“1. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 703-711.	2.9	24
24	Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. Journal of Controlled Release, 2021, 333, 283-297.	9.9	24
25	Solid nano-in-nanoparticles for potential delivery of siRNA. Journal of Controlled Release, 2017, 257, 144-155.	9.9	23
26	The effect of Eudragit RL-100 on the mechanical and mucoadhesion properties of polycarbophil dosage forms1The results reported here form part of the dissertation projects of M.B. and T.N., completed in partial fulfilment of the requirements of their respective PhD and MSc degrees at the Hebrew University of Jerusalem. The study has been presented in part at the 22nd International Symposium on Controlled Release of Bioactive Materials, Seattle, WA, 1995.1. Journal of Controlled Release, 1997, 45, 57-64.	9.9	22
27	Urokinase Plasminogen Activator Regulates Pulmonary Arterial Contractility and Vascular Permeability in Mice. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 1015-1021.	2.9	22
28	Effects of the Superoxide Dismutase-Mimic Compound TEMPOL on Oxidant Stress-Mediated Endothelial Dysfunction. Antioxidants and Redox Signaling, 1999, 1, 221-232.	5.4	21
29	Kinetic characterization and regulation of the human retinaldehyde dehydrogenase 2 enzyme during production of retinoic acid. Biochemical Journal, 2016, 473, 1423-1431.	3.7	21
30	Urokinase-type Plasminogen Activator (uPA) Induces Pulmonary Microvascular Endothelial Permeability through Low Density Lipoprotein Receptor-related Protein (LRP)-dependent Activation of Endothelial Nitric-oxide Synthase. Journal of Biological Chemistry, 2011, 286, 23044-23053.	3.4	19
31	Topical nano-encapsulated cyclosporine formulation for atopic dermatitis treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102140.	3.3	18
32	The fibrinolytic system attenuates vascular tone: effects of tissue plasminogen activator (tPA) and aminocaproic acid on renal microcirculation. British Journal of Pharmacology, 2004, 141, 971-978.	5.4	16
33	The dose-dependent effect of a stabilized cannabidiol nanoemulsion on ocular surface inflammation and intraocular pressure. International Journal of Pharmaceutics, 2022, 617, 121627.	5.2	14
34	Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 214-223.	4.3	11
35	Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug. Journal of Drug Targeting, 2019, 27, 590-600.	4.4	8
36	Development of 3-nitratomethyl-proxyl (NMP): A novel, bifunctional superoxide dismutase-mimic-nitric oxide-donor. Drug Development Research, 2000, 50, 528-536.	2.9	4

#	Article	IF	Citations
37	Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model. Current Cancer Drug Targets, 2013, 13, 11-29.	1.6	4
38	Biodistribution and efficacy of the anticancer drug, oxaliplatin palmitate acetate, in mice. International Journal of Pharmaceutics, 2021, 604, 120740.	5.2	3
39	A simple approach discriminating cardio-safe drugs from toxic ones. Bioinformation, 2009, 3, 389-393.	0.5	3
40	Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma. Oncogene, 2021, 40, 334-344.	5.9	1
41	Minit-Livin Conjugated to Targeted Nanoparticles Inhibits Tumorigenicity. Blood, 2018, 132, 4171-4171.	1.4	0